SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Novela, C.
Right arrow Articles by Hennekens, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Novela, C.
Right arrow Articles by Hennekens, C. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Hypothesis: Atorvastatin Has Pleiotropic Effects that Translate into Early Clinical Benefits on Cardiovascular Disease

Cristina Novela, MD

Department of Medicine, Mount Sinai Medical Center-Miami Heart Institute, Miami Beach, Florida

Charles H. Hennekens, MD, DrPH

Departments of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Miami, Florida; Agatston Research Institute, Miami Beach, Florida; MD, 2800 South Ocean Boulevard, PHA, Boca Raton, FL 33432; PROFCHHMD{at}prodigy.net

The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become apparent only after about 2 years. In contrast, atorvastatin conferred an early clinical benefit in the lipid-lowering arm of the long-term Anglo Scandinavian Cardiac Outcomes Trial as well as early benefit on progression of atherosclerosis in the Reversal of Atherosclerosis with Aggressive Lipid Lowering trial. An unexpected finding at baseline in the prospective Interaction of Atorvastatin and Clopidogrel Study was that patients on atorvastatin had significantly decreased platelet activity compared with either patients on other statins or those taking no statins. Atorvastatin has protective effects against membrane lipid peroxidation at pharmacologic concentrations. These and other considerations contribute to the hypothesis that atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.

Key Words: hypothesis • atorvastatin • pleiotropy

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 1, 61-63 (2004)
DOI: 10.1177/107424840400900i109
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
U. Aydin, M. Ugurlucan, F. Gungor, S. Ziyade, B. Inan, M. Banach, Y. Kalko, and T. Yasar
Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model
Angiology, June 1, 2009; 60(3): 370 - 377.
[Abstract] [PDF]


Advertisement